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Abstract 
Background 
Prevalence studies usually depend on self-report of disease status in survey data or 
administrative data collections and may over- or under-estimate disease prevalence. The 
establishment of a linked data collection provided an opportunity to explore the accuracy and 
completeness of capture of information about diabetes in survey and administrative data 
collections. 
Methods 
Baseline questionnaire data at recruitment to the 45 and Up Study was obtained for 266,848 
adults aged 45 years and over sampled from New South Wales, Australia in 2006–2009, and 
linked to administrative data about hospitalisation from the Admitted Patient Data Collection 
(APDC) for 2000–2009, claims for medical services (MBS) and pharmaceuticals (PBS) from 
Medicare Australia data for 2004–2009. Diabetes status was determined from response to a 
question ‘Has a doctor EVER told you that you have diabetes’ (n = 23,981) and augmented 
by examination of free text fields about diagnosis (n = 119) or use of insulin (n = 58). These 
data were used to identify the sub-group with type 1 diabetes. We explored the agreement 
between self-report of diabetes, identification of diabetes diagnostic codes in APDC data, 
claims for glycosylated haemoglobin (HbA1c) in MBS data, and claims for dispensed 
medication (oral hyperglycaemic agents and insulin) in PBS data. 
Results 
Most participants with diabetes were identified in APDC data if admitted to hospital (79.3%), 
in MBS data with at least one claim for HbA1c testing (84.7%; 73.4% if 2 tests claimed) or in 
PBS data through claim for diabetes medication (71.4%). Using these alternate data 
collections as an imperfect ‘gold standard’ we calculated sensitivities of 83.7% for APDC, 
63.9% (80.5% for two tests) for MBS, and 96.6% for PBS data and specificities of 97.7%, 
98.4% and 97.1% respectively. The lower sensitivity for HbA1c may reflect the use of this 
test to screen for diabetes suggesting that it is less useful in identifying people with diabetes 
without additional information. Kappa values were 0.80, 0.70 and 0.80 for APDC, MBS and 
PBS respectively reflecting the large population sample under consideration. Compared to 
APDC, there was poor agreement about identifying type 1 diabetes status. 
Conclusions 
Self-report of diagnosis augmented with free text data indicating diabetes as a chronic 
condition and/or use of insulin among medications used was able to identify participants with 
diabetes with high sensitivity and specificity compared to available administrative data 
collections. 
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Background 
Surveys and questionnaires are frequently used in health research to collect information about 
socio-demographic characteristics, functional health status, access to health care, and 
presence of lifestyle and other risk factors [1-5]. The reliability, validity and consistency of 
self-report of health status and receipt of health care have been issues of concern for health 
researchers. Under-reporting of conditions may occur because people have not been formally 
diagnosed, or chose not to reveal this information, or do not relate the condition to the 
particular situation or timeframe in which the information was sought. Some studies have 
found that the reliability of reporting is better for conditions where there are clear diagnostic 
criteria such as diabetes than for conditions where the diagnostic criteria are less clear such as 
chronic obstructive pulmonary disease [6]. Reliability of reporting can also be influenced by 
personal characteristics such as age and gender [6]. Prevalence estimates based on self-report 
under-enumerate actual population rates [2,4]. This was highlighted by the Australian 
Diabetes, Obesity and Lifestyle Study (AusDiab) study which reported that only 
approximately half of adults who participated in clinical testing for diabetes and subsequently 
were diagnosed with diabetes actually reported a prior diagnosis [2]. 
Administrative data collections represent alternative sources of information on health status 
and access to health care [6]. Although these exist primarily for the purposes of managing 
and operating health services, they are increasingly used in health services research. In 
Australia, there are four main sources of administrative data for diabetes: the National 
Diabetes Services Scheme (NDSS), Medicare Australia data and hospital morbidity data 
collections. The NDSS is a voluntary support services for Australians with diabetes and 
provides access to subsidised diabetes management products and services. Registration is 
through general practice and coverage of up to 80-90% of Australians with diabetes is 
reported. Medicare Australia is the country’s universal health insurance scheme and 
administers claims for subsidised medical care under the Medical Benefits Schedule (MBS) 
schedule and for pharmaceutical products under the Pharmaceutical Benefits Schedule (PBS). 
These claim data may under- or over-estimate diabetes care provision and diabetes 
prevalence due to subsidy rules. For example, claims for pathology testing recorded in MBS 
data are limited to a maximum of four tests in a patient episode for a set of pathology 
services, ordered by a general practitioner for a non-hospitalised patient [7]. Among a battery 
of tests, this ‘coning’ will limit claims to the four most expensive tests and may under-capture 
claims for HbA1c tests. Over-estimation based on HbA1c testing may also occur if the test is 
being used for other purposes such as screening. Dispensed medications with prices lower 
than the general patient co-payment ($34.20 as at 2011) or private scripts are not captured in 
PBS data. In New South Wales (NSW) inpatient data are recorded in the Admitted Patient 
Data Collection (APDC), and these data include details about episodes of care for people who 
are admitted. However, according to Australian Coding Standard for Additional Diagnoses 
(ACS0002) the recording of diabetes as an additional diagnosis is only required if diabetes 
affects patient management during hospital admission [8]. Population data that includes 
diagnostic testing such as AusDiab data rarely exists [9]. 
Thus variable estimates of prevalence occur due to uneven population coverage, the age 
group reported, currency of the data source, and frequency of updates to the data source. The 
prevalence of diabetes for all ages based on self-reported data from Australia’s National 
Health Survey was 3.3% in 2004-5 [10] and from the South Australian Omnibus Survey in 
2003 among people aged 15 years or older was 6.7% [5]. Prevalence rates based on 
administrative data collected during 2004–5 including NDSS (3.6%), MBS (3.0%) and PBS 
(3.0%) were similar [10]. Although somewhat old now (1999–2000) the Australian Diabetes 
and Lifestyle Study baseline data reported a self-reported prevalence of 3.7% and further 
undiagnosed (following testing) prevalence of 4.2% in adults aged 25 years or more [2]. 
Baseline data from the 45 and Up Study of NSW residents aged 45 years or older found a 
prevalence of 8.8% [11]. 
Record linkage provides an opportunity to explore the accuracy and completeness of capture 
of information about diabetes in survey and administrative data collections. We were unable 
to identify other studies comparing self-reported diabetes status with administrative data 
collections. Studies that validate quality of care measures suggest that patients overestimate 
testing procedures compared to medical records [12,13]. This paper reports a record linkage 
study using self-reported data from a baseline questionnaire completed at recruitment to the 
45 and Up Study linked to record extracts from administrative data collections including 
MBS, PBS and APDC. The baseline data provided complete enumeration of the cohort 
whereas not every cohort participant was identified in each of the administrative data 
collections. The aim of this study is to compare and contrast indicators of prevalent diabetes 
among the linked data. A secondary aim was to test an algorithm to differentiate type 1 and 
type 2 diabetes. Specifically we wanted to demonstrate the value of self-report of diabetes 
status in establishing a diabetes cohort using record linkage. This is a part of a larger study 
which is investigating the relationship between primary health care and health outcomes in 
people with diabetes. 
Methods 
Study population 
The 45 and Up Study is a population-based cohort study of NSW residents aged 45 years and 
older. It is described in detail elsewhere [11]. Briefly, recruitment was undertaken between 
2006 and 2009. Potential participants were randomly selected from the Medicare Australia 
database (Australia’s universal public health insurance system). Participants joined the Study 
by completing a mailed self-administered questionnaire and providing consent for long term 
follow-up, including linkage to personal health records. The response rate was 18% [11]. This 
current study used baseline questionnaire data from 266,848 participants. 
Detection of diabetes status and diabetes medication from baseline 
questionnaire 
The questionnaire completed at recruitment is available at 
http://www.saxinstitute.org.au/ourwork/45-up-study/questionnaires. The participants could 
indicate their diabetes status through their responses to three questionnaire items. Most 
participants with diabetes were identified from tick box responses to Question 24: ‘Has a 
doctor EVER told you that you have diabetes?’. Participants who responded affirmatively to 
this question were asked to indicate ‘Age when condition was first found’. Participants could 
also indicate a diagnosis of diabetes in a free-text box response to Questions 26: ‘Are you 
NOW suffering from any other important illness?’ The SAS Perl regular expression function 
[14] which matches and allocates text patterns in string variables was used to search for 
mention of diabetes among data from participants who did not report a diagnosis of diabetes 
using the tick box in Question 24. Free-text box responses containing ‘diabetes-like’ 
keywords were manually examined to identify additional participants with diabetes. These 
participants were categorised as having diabetes if they wrote diabetes-specific text such as 
diabetes, sugar diabetes, diabetes type 1, diabetes type 2, grade 2 diabetes, self-management 
or controlled diabetes. Participants writing text such as pre-diabetes, borderline diabetes, or 
diabetes insipidus were categorised as ‘diabetes uncertain’. 
The self-reported use of diabetes medications was also identified from the baseline 
questionnaire. Question 23 asked ‘Have you taken any medications, vitamins or supplements 
for most of the last 4 weeks, including HRT and the pill?’ Medications for diabetes could be 
identified from the tick box for Diabex, Diaformin, or Metformin, and a text box for other 
diabetes related medications. A list of the different types and brand names of insulin products 
and oral hypoglycaemic agents (OHA) available in Australia was accessed [15] (Table 1) and 
searched, using the SAS Perl function [14] (false negative rate of 1.7% for insulin and OHAs, 
false positive rates for insulin and OHAs ranged between 0% and 1.06%). Participants who 
reported use of insulin but did not indicate a diagnosis of diabetes in other fields (n = 58) 
were added to the diabetes group while those who reported only OHAs were included in the 
‘diabetes uncertain’ group. We did not attempt to identify incident cases of diabetes. 
Table 1 Insulin products and oral hypoglycaemic agents (OHA) available in Australia 
and self-reported use by 45 and Up Study participants at recruitment 
Medications self-reported Number 
Insulin 2,379 
Any oral hypoglycaemic agents (OHAs) 14,124 
 Biguanides 12,560 
 Sulphonylureas 3,766 
 Thiazolidinediones 855 
 Alpha glucosidase inhibitor 72 
 Inhibitor DipeptidylPeptisase 4 inhibitor 50 
 Pre-mixed tablets 196 
Exenatide 17 
Meglitinides 6 
Finally, we attempted to classify diabetes as type 1, type 2, or other based on additional 
information including age at diagnosis, medication use, and age at birth of their last child (for 
females). Participants who either reported type 1 diabetes in free-text fields, were diagnosed 
before age of 31 years [16] and were using insulin, or did not give age of diagnosis but were 
using insulin were classified as having type 1 diabetes. Women who were diagnosed before 
the date of last delivery and did not report current medication use were classified as having 
(had) gestational diabetes. The remainder were classified as having type 2 diabetes. 
Validation of self-report diabetes status 
Diabetes status identified from the 45 and Up questionnaire was compared with diabetes 
status reported in the APDC, and MBS and PBS claims using record linkage. The APDC is a 
mandated record of all patient admissions to NSW hospitals. Data between 1 July 2000 and 
31 December 2009 were extracted. Patient diagnoses are coded as principal diagnosis and 
additional (>10) diagnoses using ICD10-AM codes [8]. Diabetes diagnoses in the APDC 
were identified from all diagnostic fields using ICD10-AM codes (E10, E11, E13, E14, and 
O24.0-O24.3) and were classified as Type 1, Type 2, and other type of diabetes. The 45 and 
Up Study data and APDC were linked using ‘best practice protocols’ for preserving 
individual privacy by the Centre for Health Record Linkage (CHeReL), an independent data 
linkage facility [17]. Personal information such as name, date of birth, sex and address was 
used for linkage. 
The MBS data records all claims for medical and diagnostic services provided through 
Medicare. Claims for glycosylated haemoglobin (HbA1c) testing (item number 66551) 
between 2004 and 2009 were extracted. HbA1c testing is used as a measure of glucose 
control for people with diabetes and should be performed at least annually for all people with 
diabetes [15]. Medicare data were linked by Department of Human Services using 
deterministic techniques based on a unique identifying number and other personal identifying 
information. 
Validation of self-report diabetes medications 
Self-reported medication use was compared with available claims for dispensing of insulin 
and oral hypoglycaemic agents (OHA) products recorded in the PBS data for 12 months prior 
to recruitment. Medications provided to war veterans are not included in the PBS, so 
participants who reported possessing a Department of Veteran Affairs (DVA) card were 
excluded from this analysis (n = 6,303). (OHA use was tested in concession card holders 
only) 
Analysis 
As described above, participants were categorised into one of three diagnostic groups: 
diabetes, non-diabetes, and diabetes uncertain. Data from participants in the ‘uncertain’ group 
were analysed separately. 
The diabetes and non-diabetes groups were compared to the criterion standard of each linked 
data collection. The criterion standards used were: confirmed having diagnosis of diabetes in 
diabetes ICD-10-AM codes recorded in APDC data, a claim for (1 or 2) HbA1c tests in MBS 
data and a claim for a dispensed prescription for insulin or OHA in the PBS data. We 
constructed two by two tables and calculated sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV), and Kappa agreement. Using administrative data as 
the imperfect ‘gold’ standard, sensitivity refers to the proportion of participants with diabetes 
according to criterion standard of each linked administrative data collection who were 
assigned to the diabetes group, whereas specificity refers to the proportion of participants 
without diabetes according to criterion standard of each linked administrative data collection 
who were not assigned to the diabetes group [18]. The PPV refers to the proportion of 
participants in the 45 and Up Study assigned to the diabetes group who were also found to 
have diabetes according to the relevant criterion standard. The NPV is the proportion of 
participants who were assigned to the non-diabetes group without diabetes according to the 
criterion standard. The Kappa statistic provides an error-corrected measure of agreement 
between two measures of a categorical variable without assuming either source as the gold 
standard. It was calculated using Fleiss’ formula [19]. 
Ethics 
The 45 and Up Study was approved by the University of New South Wales Human Research 
Ethics Committee. The specific study reported here was approved by the NSW Population 
and Health Services Ethics Committee, Cancer Institute NSW (reference 2010/05/228 and 
2010/05/229). 
Results 
Report of diabetes status from baseline 45 and Up questionnaire 
Data provided by 266,848 NSW residents at recruitment to the 45 and Up Study were 
extracted. The distribution of diabetes is summarised in Figure 1. A prior diagnosis of 
diabetes was reported by 23,981 (9.0%) participants. On examination of the ‘free text’ field, a 
further 255 participants wrote diabetes related words, 119 of whom were considered to have 
current diabetes and 136 whose diabetes status was uncertain. Examination of the medication 
use fields for the remaining 242,612 participants identified 1,246 participants taking OHAs 
and 58 using insulin. Participants who were using insulin were included in the diabetes group, 
while those in the OHA group who did not tick the diabetes diagnosis box were assigned to 
diabetes uncertain group. In total 24,158 individuals were assigned to the diabetes group, 
giving a revised reported prevalence of diabetes of 9.05%. 
Figure 1 Algorithm for identifying diabetes status among participants at recruitment 
using information reported during completion of a baseline questionnaire. 
Validation of self-reported diabetes status from the 45 and Up Study 
Validation against APDC diagnostic codes 
There were 193,126 (19,086 in the diabetes group, and 153 uncertain) participants in the 45 
and Up Study with an identified hospital admission between 2000 and 2009. 45 and Up Study 
participants could not be linked to data held by the CHeReL (n = 77), were not admitted to 
hospital during study period (n = 72,953), or were diagnosed with diabetes since their last 
hospital admission (n = 692) were excluded from this analysis. Participants with a diagnosis 
of gestational diabetes and not other forms of diabetes in the APDC data were excluded from 
further analysis. 
Among 45 and Up Study participants assigned to the diabetes group (n = 19,086), 79.3% (n = 
15,143) had a diagnosis of diabetes recorded in APDC (PPV); among participants assigned to 
the non-diabetes group, 98.3% (n = 169,983) did not have diabetes recorded in the APDC 
(NPV, Table 2). Using APDC as the standard the sensitivity was 83.9%, specificity 97.7%, 
and Kappa for agreement was 0.8. About half of those assigned to the diabetes uncertain 
group at baseline (n = 557; 48.3%) had diabetes recorded in the APDC. 
Table 2 Agreement between self-report of diabetes status by 45 and Up Study 
participants at recruitment and at least one diagnostic code for diabetes reported in 
APDC data 2000–9 
Self-report of diabetes APDC diabetes status Total 
Diabetes Non-diabetes  
Diabetes 15,143 3,943 19,086 
Non-diabetes 2,904 169,983 172,887 
Total 18,047 173,926 191,973# 
Uncertain* 557 596 1153 
* Not included in the agreement analyses. 
#
 Data limited to participants with record of hospital admission during 200–9. 
Validation of diabetes against claims for HbA1c testing in MBS data 
Of the 266,848 45 and Up Study participants, 265,052 successfully linked to MBS data 
(including 24,004 in the diabetes group and 1,377 in the diabetes uncertain group). 
Participants whose data did not link to MBS (n = 1,783) or whose year of diagnosis with 
diabetes was later than 2009 (n = 13) were excluded from this analysis. During the five years 
2005–09, 32,641 participants (12.3%) had at least one MBS claim for an HbA1c test; 22,467 
(8.5%) had two claims; 17,663 (6.7%) had three claims; and 14,182 (5.4%) had at least four 
claims for an HbA1c test. 
Table 3 presents the cross-tabulations between self-reported diabetes status from the 45 and 
Up Study and at least one claim for an HbA1c test. Among 45 and Up Study participants 
assigned to the diabetes group (n = 24,004), 84.7% (n = 20,340) had a claim for a HbA1c test 
recorded (PPV); among participants assigned to non-diabetes group, 95.2% (n = 228,157) did 
not have a claim for a HbA1c test recorded (NPV, Table 2) (73.4% and 98.2% respectively if 
two claims for HbA1c testing were considered). Using claims for HbA1c tests as the 
standard, the sensitivity was 63.9%, specificity was 98.4%, and Kappa was 0.7 (80.4%, 
97.4%, and 0.75 respectively if two claims for HbA1c testing were considered). About half (n 
= 787; 57.2%) of those of uncertain diabetes status at recruitment had at least one record of 
an HbA1c test, suggesting presence of diabetes. 
Table 3 Agreement between self-report of diabetes status by 45 and Up Study 
participants at recruitment and claims for at least 1 HbA1c test during 2005 - 2009 
Self-report of diabetes HbA1c testing status Total# 
yes no  
Diabetes 20,340 3,664 24,004 
Non-diabetes 11,514 228,157 239,671 
Total 31,854 231,821 263,675 
Uncertain* 787 590 1,377 
* Not included in the agreement analyses. 
#
 Data limited to participant data that linked successfully to MBS data. 
Validation of self-reported medication use against claims for diabetes medication 
recorded in PBS data 
Of the 266,848 participants in the 45 and Up Study, 213,287 participants linked to PBS data, 
did not report DVA card at baseline, and had at least one claim for medication during the 12 
months prior to recruitment. 
At baseline of 24,151 participants in the 45 and Up Study assigned to the diabetes group, 
10% (n = 2,379) self-reported using insulin and 58% (n = 13,962) self-reported OHAs. In the 
linked data, 71.4% (n = 14,465) of participants with diabetes had a record of at least one PBS 
claim for diabetes-related medication during the 12 month prior to enrolment and 99.7% 
(191,068) of those assigned to the non-diabetes group did not have a claim recorded for 
diabetes-related medication. 
Table 4 presents the cross-tabulations between self-reported diabetes status from the 45 and 
Up Study and at least one claim for insulin or OHA from the PBS. Using the PBS data as the 
standard the sensitivity was 95.6%, the specificity was 97.1% and the Kappa was 0.8. About 
two thirds (n = 770; 66.2%) of those whose diabetes status at baseline was uncertain has a 
claim for diabetes-related medication. 
Table 4 Agreement between self-report of diabetes status by 45 and Up Study 
participants at recruitment and claims for diabetes related medication (Insulin and/or 
OHAs) in the 12 months prior to recruitment 
Self-report of diabetes Diabetes related medication Total# 
yes no  
Diabetes 14,465 5,780 20,245 
Non-diabetes 663 191,068 191,731 
Total 15,128 196,848 211,976 
Uncertain* 770 394 1,164 
* Not included in the agreement analyses 
#
 Data limited to participants that linked successfully to PBS data and met inclusion criteria. 
Determination of type of diabetes 
Our algorithm for determining the type of diabetes among the 24,158 participants assigned to 
the diabetes group is summarised in Figure 2. Using the free text field, 258 participants 
indicated that they had type 1 diabetes and 1,504 indicated that they had type 2 diabetes. 
Participants who reported using insulin products AND who reported diagnosis before age 31 
(n = 559) or did not provide an age of diagnosis (n = 62) were categorised as type 1 diabetes. 
Women who gave their age of diagnosis before the birth of their last child and were not 
currently using diabetes medication were categorised as gestational diabetes. This process 
resulted in 899 participants categorised as type 1, 22,789 as type 2 and 470 as ‘other’. 
Figure 2 Algorithm for classifying type of diabetes (Type1, Type 2, Other) for 
participants who reported diabetes at recruitment and using information reported 
during completion of a baseline questionnaire. Footnote: data limited to 24,158 
participants categorised to the diabetes group. 
Table 5 illustrates the agreement between diabetes type identified using our algorithm and 
diabetes type as indicated in the APDC data for participants with diabetes with a record of 
hospital admission. Among the 18,000 participants in the 45 and Up Study baseline data who 
were assigned to Type 2 diabetes using the algorithm, 76.8% had a diagnosis of type 2 
diabetes recorded in the APDC data. However, among the 756 identified assigned to Type 1 
diabetes using our algorithm, only 41.5% had a diagnosis of Type 1 diabetes recorded in the 
APDC data. 
Table 5 Agreement between algorithm for assigning diabetes type based on baseline 
questionnaire data reported by 45 and Up Study participants and diabetes type 
recorded in APDC data 2000-9 
Diabetes type 
from baseline 
Diabetes type – APDC Total 
Type 1 Type 2 Gestational 
/Other 
Unspecified Diabetes not 
recorded 
 
Type 1 314 383 2 1 56 756 
Type 2 451 13822 18 45 3664 18,000 
Gestational/other 26 61 20 0 223 330 
Total 791 14,266 40 46 3,943 19,086# 
#
 Data limited to 45 and Up participants with diabetes with a record of hospital admission 
during 200–9 
Discussion 
This study explores the criterion validity of identifying participants with diabetes from 
information they provided at recruitment to the 45 and Up Study. Most participants (99%) 
with diabetes self-reported their diabetes status through a tick box response; the remainder 
wrote diabetes in free text field (n = 119) or reported insulin use (n = 58). The final 
prevalence of diabetes was 9.05% (n = 24,158). Compared to the other data collections, more 
than 80% of those who self-reported diabetes were found to have a record of a diagnosis of 
diabetes or diabetes-related treatment in linked data collections. There were 1,382 
participants (0.5%) whose diabetes status was uncertain based on self-reported information 
about their diabetes status. Although about half of this ‘diabetes uncertain’ group may also 
have diabetes and the remainder may have a pre-diabetic condition, we excluded all from 
consideration in this study. Our algorithm to differentiate type of diabetes was not useful to 
exclude participants with type 1 diabetes from the study. 
The strength of this study is the large population based sample and the unit record linkage to 
administrative data collections on claims for occasions of care and events such as 
hospitalisation. Although a low response rate to invitation to participate was observed, 
research has demonstrated that for a broad range of risk factors, this study yielded consistent 
estimates of exposure-outcome relationships as a population survey of the same population 
that reported varying response rate, sampling frame and mode of questionnaire administration 
[20]. The main short coming of this study is the absence of the results of diagnostic or other 
clinical findings to confirm a diagnosis of diabetes among participants. The study relied on 
responses to a general question ‘Has a doctor EVER told you that you have diabetes?’ as the 
primary means of identifying those participants with diabetes. As indicated from additional 
information available to this study diabetes status could be under-reported through not 
responding to this question or over-reported in circumstances where diabetes was not longer 
present for example, gestational diabetes or weight loss. This would not fully explain 
differences between the different data sets. The questions included in the baseline 45 and Up 
Study questionnaire did not enable further exploration of diabetes status through seeking 
additional specific information on diagnosis and care received [21]. Although the 
administrative data extracts included data collected over a number of years, we have 
presented a cross-sectional analysis for this study. 
Our approach to exploring the reliability of self-report of diabetes was to compare self-report 
to evidence of a diagnosis of diabetes or diabetes-related testing in the linked data collections. 
Identification using APDC excluded those patients who were not admitted during data (2000–
2009). We found that 80% of participants self-reporting diabetes had a diagnosis of diabetes 
recorded in APDC; both sensitivity and specificity were high. Using claims for HbA1c 
testing may over-identify participants with diabetes due to the misuse of this test for 
screening and other purposes. This was confirmed with lower sensitivity (64%) and Kappa 
(0.7) which improved to 80.4% and 0.75 when claims for receipt of two HbA1c tests were 
considered. However, for the diabetes group identified at baseline, our study found that 85% 
had a record of one or more HbA1c test (73.4% had two or more), confirming the self-report 
of diabetes in this group. Although it has been suggested that ‘coning’ may lead to an 
underestimation of diabetes status [7] and this might explain the lower agreement between 
baseline 45 and Up data and claims for HbA1c testing, we could not explore this in the 
available data. In regard to our comparison to claims for diabetes related medications 
recorded in the PBS data, 71% of participants with diabetes had at least one claim for 
medication in the 12 months prior to recruitment. We observed a high level of agreement 
(Kappa: 0.8). One reason that only 71% of participants had a prescription for diabetes related 
medication might be because some medications may cost less than the patient co-payment 
and thus may not have been recorded in PBBS data during the study period. Some 
participants are also likely to be controlled by diet alone although we could not demonstrate 
this in the current data. However, self-reported diabetes medication (Insulin: 10%; OHAs: 
58%) was similar to that observed in the PBS data (71%). 
Our algorithm identified a small group of participants whose diabetes status was classified as 
uncertain. These included 136 participants who did not use the tick box but wrote words for 
conditions such as pre-diabetes or diabetes insipidus and 1,246 participants who did not self-
report diabetes but who did report use of oral hypoglycaemic agents. Using additional data 
that was available through linkage, it is likely that about half of these participants actually 
have a diagnosis of diabetes that was incorrectly reported at baseline. 
The recruitment questionnaire did not seek information on type of diabetes. We attempted to 
use additional data provided within the questionnaire to identify those participants who had 
type 1 diabetes. Our algorithm could identify less than half of participants with type 1 
diabetes identified in the APDC. As these data do not include all participants in the 45 and 
Up Study (74% of participants had a hospital admission identified in the 10 year period), it 
was not possible to use APDC data as an alternate source of diagnosis. 
We have identified some differences in reporting of diabetes status between these data 
collections. Firstly, self-report accurately identified at least 80% of participants in the 45 and 
Up Study with a diagnosis of diabetes. This is similar to the proportion who self-identified in 
the AusDiab study where self-report of diabetes was confirmed by biological testing 
(unpublished data) and suggests that the general question relating to diabetes status was 
adequate to identify a sub-population of people with diabetes participating in the 45 and Up 
Study. We are not able to comment on the implications of the findings of the AusDiab study 
that about half of people with diabetes were not diagnosed at testing. While some under-
diagnosis is suggested from the APDC where 16% of participants identified with diabetes on 
admission did not self-report a diagnosis of diabetes, 21% of participants who self-reported a 
diagnosis at baseline did not have a diagnostic code for diabetes in their admission data. 
Although HbA1c testing is intended for monitoring control of blood sugars among people 
with diabetes, the low sensitivity and specificity of HbA1c from a single test, that improved 
when limited to two or more tests, limits the value of this test in identifying a population 
sample of people with diabetes from the universal health insurance data base. We did not 
explore the role of other tests, such as diabetes service incentive payments (SIP) for 
completion of an annual cycle of diabetes care, as these were only claimed for 25% of our 
diabetic study population [22]. Efforts to create a ‘pseudoSIP’ based on claims for 
components of the annual cycle of care were not consistent with claims for SIP and were not 
pursued. These results have implications for national data systems using this means of 
identification of the incidence and prevalence of diabetes; in particular, the use of the HbA1c 
test as an indicator of a diagnosis of diabetes is increasingly unsatisfactory due to changes in 
the eligibility criteria for testing and its more widespread use as a screening test for diabetes. 
In turn, there are implications for the Australia Medicare Diabetes Practice Incentive 
Payment which uses the number of HbA1c test claimed to determine the denominator for 
calculating the proportion of standardised patient equivalents that have completed their 
annual cycle of care. 
Overall the use of survey and administrative data collections pose challenges in identifying 
community based populations with diabetes; self-report may under- or over-estimate diabetes 
prevalence; APDC depends on admission and recording of diabetes if not directly related to 
the admission; and MBS and PBS claims depend on the availability of claims for specific 
tests. 
Conclusion 
This study formed part of preparatory work in a larger research project to identify participants 
within the 45 and Up Study with a diagnosis of diabetes. A combination of self-reported 
diabetes augmented with free text data in which a participant reported diabetes as a chronic 
condition and/or use of insulin among medications used was able to identify participants with 
diabetes with high sensitivity and specificity compared to available administrative data 
collections. Using these methods, the diabetes status of a number of participants was found to 
be uncertain; we have made a decision to exclude these participants from further study. We 
developed an algorithm to classify participants’ diabetes status into type of diabetes but, due 
to insufficient information, this was found to be not reliable. 
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